View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
April 21, 2020

Genedrive and Cytiva to develop PCR assay for coronavirus

Genedrive has partnered with Cytiva, formerly called GE Healthcare Life Sciences, for the development of an assay to detect SARS-CoV-2, which causes Covid-19.

Molecular diagnostics company Genedrive has partnered with Cytiva, formerly called GE Healthcare Life Sciences, for the development of an assay to detect SARS-CoV-2, which causes Covid-19.

Free Report
img

Build resilience in the face of COVID-19 disruption

COVID-19 has already affected our lives forever. The way we work, shop, eat, seek medical advice, and socialize will all be different in the future. Quite how different remains to be seen, but all industries must plan for multiple eventualities. Are you interested in actionable insights on the business challenges induced by the pandemic? GlobalData's cross-sector report analyzes the significance of this major disruptive theme across industry verticals. It provides side-by-side research of alternative datasets to present you with unique quantitative analysis of the effects of COVID-19 and how these differ across sectors. Additionally, it offers qualitative analysis of each sector and analyzes COVID-19’s impact on leading companies. Whatever your company’s imminent strategic plans, the long-lasting impact of COVID-19 must not be overlooked. Find out how to futureproof your business operations – download our report today.
by GlobalData
Enter your details here to receive your free Report.

The new test, called Genedrive 96 SARS-CoV-2 assay, is being developed for use on polymerase chain reaction (PCR) instruments in laboratories.

Designed as a one-step, ready-to-go freeze-dried assay, the test leverages Genedrive’s PCR chemistry along with Cytiva’s LyoStable stabilisation technology.

The combination is expected to facilitate high-throughput manufacturing of more than 10,000 tests per hour with a 96-well, temperature-stable plate format that does not require refrigeration.

Genedrive 96 SARS-CoV-2 assay consists of a single PCR bead that can be mixed with a patient’s sample, allowing the test to be performed on existing open PCR platforms, including those from Roche and ABI (Thermo Fisher).

Genedrive CEO David Budd said: “We have extensive experience working with the Cytiva team on assay development and manufacturing for our point-of-care HCV, AIHL and military programmes.

“We are pleased to now apply that partnership in a high-throughput manufacturing process, which we believe places us amongst a small group of companies that have the capability to produce simple assay solutions at significant scale.”

The partners aim to make the assay available in the next five weeks. In alliance with Cytiva, Genedrive hopes to deliver a consistent and reproducible assay that can be manufactured in high volume.

Cytiva Genomics and Diagnostics general manager Gabriel Fernandez de Pierola said: “Critical to overcoming the pandemic is being able to produce high volumes of reliable tests, which can be shipped easily on a global basis with minimal environmental impact.

“We hope our Lyo-Stable technology coupled with Genedrive’s high-throughput testing solution will help deliver technical solutions to address the current crisis.”

Genedrive is also working to develop a second point-of-care SARS-CoV-2 test that will use its formulations to run on the Genedrive instrument platform.

Related Companies

Free Report
img

Build resilience in the face of COVID-19 disruption

COVID-19 has already affected our lives forever. The way we work, shop, eat, seek medical advice, and socialize will all be different in the future. Quite how different remains to be seen, but all industries must plan for multiple eventualities. Are you interested in actionable insights on the business challenges induced by the pandemic? GlobalData's cross-sector report analyzes the significance of this major disruptive theme across industry verticals. It provides side-by-side research of alternative datasets to present you with unique quantitative analysis of the effects of COVID-19 and how these differ across sectors. Additionally, it offers qualitative analysis of each sector and analyzes COVID-19’s impact on leading companies. Whatever your company’s imminent strategic plans, the long-lasting impact of COVID-19 must not be overlooked. Find out how to futureproof your business operations – download our report today.
by GlobalData
Enter your details here to receive your free Report.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. The top stories of the day delivered to you every weekday. A weekly roundup of the latest news and analysis, sent every Friday. The medical device industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Medical Device Network